Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
SHARE THIS ARTICLE
Cadrenal Therapeutics (CVKD) has announced a significant collaboration agreement with Abbott (ABT) to support their pivotal TECH-LVAD trial, evaluating tecarfarin in patients with Left Ventricular Assist Devices (LVADs).
The collaboration focuses on testing tecarfarin, a new oral Vitamin K antagonist (VKA), with Abbott's HeartMate 3™ LVAD, which is currently the only advanced mechanical circulatory support device available in the United States for patients with advanced heart failure.
Under the agreement, Abbott will provide support in:
- Trial design
- Site identification
- Trial awareness
- HeartMate 3™ expertise
The LVAD market, valued at $1.1 billion in 2023, is projected to reach $2.4 billion by 2032, according to Business Research Insights.
Positive
- Strategic collaboration with major healthcare company Abbott
- Access to key clinical trial sites and enhanced patient enrollment
- Targeting $1.1B LVAD market with projected growth to $2.4B by 2032
- First innovation in vitamin K anticoagulation in 70+ years
Negative
- Late-stage development implies significant ongoing R&D expenses
- Success dependent on clinical trial outcomes
Pharmaceutical Industry Analyst
This collaboration between Cadrenal Therapeutics and Abbott represents a significant strategicadvancement for Cadrenal's clinical development program. The agreement directly supports Cadrenal's pivotal TECH-LVAD trial for tecarfarin, their lead late-stage asset. Abbott's commitment to provide trial design expertise, site identification support, and access to HeartMate 3™ LVAD insights substantially de-risks the execution of this critical study.
The partnership provides Cadrenal with three key advantages: enhanced trial site access, improved patient enrollment capabilities, and validation from a global healthcare leader. For a company with Cadrenal's market cap ($32.7 million), securing support from Abbott significantly strengthens their clinical development position and potentially accelerates their regulatory pathway.
The LVAD market represents a substantial commercial opportunity, valued at $1.1 billion in 2023 with projected growth to $2.4 billion by 2032. Tecarfarin aims to address a critical medical need as potentially the first innovation in vitamin K-targeted anticoagulation in over 70 years. Successful development could position it as a preferred anticoagulant for LVAD patients.
While financial terms weren't disclosed, the non-monetary contributions from Abbott appear substantial. The collaboration structure focuses on clinical development support rather than direct investment, suggesting Abbott sees potential value in improving anticoagulation outcomes for their HeartMate 3™ LVAD patients, which could create future commercial synergies between the two companies' products.
Cardiology Medical Device Expert
This collaboration targets a critical unmet need in advanced heart failure management. Anticoagulation therapy is essential for LVAD patients to prevent thromboembolic complications, but current options present significant clinical challenges. Abbott's HeartMate 3™ LVAD, while the most advanced device in the U.S. market, still requires effective anticoagulation management to optimize patient outcomes.
The technical value of this partnership lies in combining Abbott's device expertise with Cadrenal's specialized anticoagulant. Abbott's willingness to share insights from recent HeartMate 3™ trials suggests they recognize potential benefits from improved anticoagulation specific to their device platform. This data sharing could help Cadrenal optimize their trial design to demonstrate tecarfarin's value specifically in this patient population.
From a clinical perspective, vitamin K antagonists have remained largely unchanged for decades despite their narrow therapeutic window and monitoring challenges. A new VKA specifically studied in LVAD patients could potentially address significant clinical management issues. The collaboration focuses on a well-defined patient population with clear anticoagulation needs, creating a focused regulatory and commercial pathway.
The strategic alignment between Cadrenal's anticoagulant therapy and Abbott's mechanical circulatory support technology could improve the overall therapeutic approach to advanced heart failure patients. If successful, this could establish a new standard of care for anticoagulation in LVAD therapy, particularly for the HeartMate 3™ platform that dominates the U.S. market.
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD),a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE: ABT) to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the Agreement, Abbott will share insights from recent HeartMate 3™ trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3™ expertise.
“We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrollment efforts,” said Quang X. Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. “Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3™ LVAD, advancing our commitment to bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years.”
Abbott’s HeartMate 3™ LVAD is a mechanical circulatory support device designed for patients with advanced heart failure. Abbott’s heart pumps have set the standard in LVAD therapy. The HeartMate 3™ LVAD is the most advanced LVAD yet and the only one currently available in the United States. According to Business Research Insights, the LVAD market was valued at $1.1 billion in 2023 and is projected to reach $2.4 billion by 2032.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developingspecialized therapeutics for rare cardiovascular conditions. The Company is developing its late-stage asset, tecarfarin, a new oral vitamin K antagonist (VKA) designed to be a better and safer anticoagulant than warfarin, for individuals with implanted cardiac devices. Although warfarin is widely used off-label for several rare cardiovascular conditions, extensive clinical and real-world data have shown it to have significant serious side effects. With its innovation, Cadrenal aims to meet the unmet needs of this patient population by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges.
Cadrenal is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted left ventricular assist devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).
Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us onLinkedIn.
Safe Harbor
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the collaboration strengthening the potential for improved patient outcomes through improvements in the quality of anticoagulation enhancing hemocompatibility in HeartMate 3™ LVAD patients; Abbott supporting Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs; Abbott sharing insight from recent HeartMate 3™ trials and supporting Cadrenal w ith: trial design, site identification, trial awareness, and HeartMate 3™ expertise; the support of Abbott further validating the advancement into late-stage clinical development of tecarfarin; bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years; meeting the unmet needs of LVAD patients by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges, Cadrenal building build a pipeline of specialized cardiovascular therapeutics and the LVAD market being projected to reach $2.4 billion by 2032. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to utilize Abbott’s expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal clinical trial for tecarfarin in LVAD patients by Cadrenal and for Cadrenal to provide improved patients outcomes and efficacy and safety for LVAD patients; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE Cadrenal Therapeutics, Inc.
Disclaimer
Effective Date: [August, 2024]
This website/newsletter is owned, operated, and edited by Relqo Media LLC. Any wording found in this email or disclaimer referencing "I," "we," "our," or "Relqo Media" refers to Relqo Media LLC. This webpage/newsletter is a paid advertisement, not a recommendation or an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website, you agree to the terms of our disclaimer, which are subject to change at any time.
We are not registered or licensed in any jurisdiction to provide investing advice or any advisory or consultancy services, and are therefore unqualified to give investment recommendations. Always conduct your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve as a starting point to conduct your own research and consult with a licensed professional regarding the companies profiled and discussed.
Conduct your own research. Companies with a low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences issues with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data.
This publication, its owners, and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, potentially impacting share prices. If we own any shares, we will list the relevant stock information and the number of shares here. Relqo Media LLC's business model is to receive financial compensation to promote public companies.
Purpose
These websites, social media accounts, and all associated content are provided for informational and entertainment purposes only. Relqo Media LLC engages in marketing, advertising, and brand awareness for small-cap public companies. The content, including articles, emails, tweets, and other communications across our platforms, is classified as paid advertisements and should not be considered an offer, recommendation, or solicitation to buy or sell securities. Readers and users should not rely on the information provided as a basis for making investment decisions.
Compensation Disclosure
Relqo Media LLC is compensated for its promotional services by Penzance LLC, and this compensation may include cash payments, stock options, or other financial consideration from the companies we feature. The compensation received directly impacts the content presented on our platforms and creates a significant conflict of interest.
Cadrenal Therapeutics: Relqo Media LLC has been compensated $30,000 per week since August 8, 2024, to run a marketing campaign for Cadrenal Therapeutics. This payment will continue until April 1, 2025, bringing the total compensation to seven hundred eighty thousand dollars.
NeoVolta Inc: Relqo Media LLC has been compensated four hundred thousand dollars starting November 11, 2024, to run a marketing campaign for NeoVolta Inc. This payment will continue until March 31, 2025. Compensation represents a major conflict of interest in our ability to remain unbiased. Therefore, this communication should be viewed as a commercial advertisement only.
We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates may wish to liquidate shares of the profiled company at or near the time you receive this communication, which could negatively impact share prices. Any non-compensated alerts are purely for the purpose of expanding our database for future financially compensated investor relations efforts. Frequently, companies profiled in our alerts may experience a significant increase in volume and share price during investor relations marketing, which may decline as soon as the marketing ceases.
Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed.
The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way to ensure its accuracy. Furthermore, Relqo Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. While independent writers' works are reviewed and edited before publication, errors or omissions may occur. You should assume all information in our communications is incorrect until you verify it yourself and are encouraged never to invest based solely on the information contained in our communications.
The information in this disclaimer is subject to change at any time without notice.
Stockverse Legal Disclaimer
Earnings & Performance Disclaimer
Stockverse provides stock market data, research tools, AI-generated insights, and other financial information strictly for educational and informational purposes.
No Guarantee of Future Performance
The past performance of any stock, security, or investment strategy does not guarantee future results. Stock markets are inherently volatile, and returns are unpredictable.
Investment Risks
Investing in stocks, securities, and financial markets carries substantial risk, including the risk of total loss of capital. Users should perform independent due diligence before making investment decisions.
No Financial Advice
Stockverse does not provide financial, investment, tax, or legal advice. Any information, data, or AI-generated insights should not be considered personalized financial advice. Users should consult a licensed financial professional before making any trading or investment decisions.
AI & Data Disclaimer
Stockverse integrates artificial intelligence (AI) technology (Stockverse GPT) and third-party financial data providers to generate stock insights and market analysis.
AI Limitations & Potential Errors
Stockverse GPT is powered by OpenAI and third-party data sources. While it provides AI-driven stock analysis, it can generate inaccurate, outdated, or misleading information. AI predictions and insights are not a substitute for professional financial analysis.
Delayed & Inaccurate Data
Stock market data displayed on Stockverse may be delayed, incomplete, or inaccurate due to exchange rules, provider limitations, or data outages. Stockverse does not guarantee the accuracy, reliability, or completeness of any financial data provided.
User Responsibility
Users acknowledge that Stockverse GPT and AI-generated insights should not be relied upon for making investment decisions. All trading and financial actions are taken at the user's sole discretion and risk.
Limitation of Liability
By using Stockverse, you acknowledge and agree that:
No Liability for Financial Losses
Stockverse, its owners, affiliates, partners, and employees shall not be liable for any direct, indirect, incidental, consequential, or financial losses incurred due to reliance on data, AI-generated insights, stock recommendations, or market trends displayed on this platform.
No Warranties
Stockverse makes no warranties or representations, express or implied, regarding the accuracy, reliability, or completeness of any content provided. All information is provided "as is" and "as available."
Third-Party Data & External Links
Stockverse may link to third-party content, stock exchanges, brokers, or news sources. We do not endorse, control, or assume responsibility for the accuracy or reliability of external websites or third-party data feeds.
Use at Your Own Risk
By using Stockverse, you acknowledge that all investment decisions are made solely at your own risk, and you release Stockverse from any and all liability associated with financial losses.
Governing Law & Dispute Resolution
Jurisdiction & Applicable Law
This Agreement and any disputes arising out of or relating to Stockverse shall be governed by and construed under the laws of the State of Wyoming, without regard to conflict of law principles.
Binding Arbitration
Any disputes, claims, or controversies arising out of or related to the use of Stockverse shall be exclusively resolved through binding arbitration in Wyoming, in accordance with the rules of the American Arbitration Association (AAA).
Waiver of Class Action & Jury Trial
By using Stockverse, you agree to waive any right to participate in a class action lawsuit or jury trial against Stockverse, its owners, affiliates, and representatives.
Intellectual Property Rights
Ownership of Content
All content, design elements, trademarks, stock analysis, AI-generated insights, and proprietary data displayed on Stockverse are owned by Stockverse Holdings LLC and protected under U.S. and international copyright and intellectual property laws.
Restrictions on Use
Users may not copy, modify, distribute, sell, or republish any Stockverse content, AI-generated insights, or proprietary tools without explicit written permission from Stockverse Holdings LLC.
AI-Generated Content & Licensing
AI-generated insights, trade signals, and stock analysis provided by Stockverse GPT are proprietary and cannot be resold, republished, or distributed for commercial use without express authorization.
DMCA & Copyright Violations
Any unauthorized reproduction or use of Stockverse content may result in legal action under the Digital Millennium Copyright Act (DMCA) or applicable intellectual property laws.
Acceptance of Terms
By accessing and using Stockverse, you acknowledge that you have read, understood, and agreed to this disclaimer. If you do not agree with any part of this disclaimer, you must discontinue use of this platform immediately.
For any legal inquiries or compliance concerns, please contact:
📧 support@stockverse.com🌐 Stockverse.com